A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.

Trial Profile

A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough - Merck & Co (JV)
  • Most Recent Events

    • 18 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Feb 2014 According to the ClinicalTrials.gov record, Status changed from recruiting to active, no longer recruiting.
    • 18 Feb 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 1 Feb 2016 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top